Crizotinib

Crizotinib is an oral medication used for the treatment of certain types of lung cancer, specifically non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as ALK gene rearrangement. This medication is designed to target and inhibit the activity of the ALK protein, which is responsible for promoting the growth and spread of cancer cells in affected individuals.
Crizotinib has been shown to significantly improve the progression-free survival of patients with advanced ALK-positive NSCLC, allowing them to live longer without their cancer worsening. In addition to its use in treating lung cancer, crizotinib has also been studied for its potential effectiveness in treating other types of cancers with ALK gene rearrangements, such as breast cancer and thyroid cancer.
The medication is typically administered orally, once daily, with or without food. It is important for patients to follow their healthcare provider’s instructions carefully regarding the dosage and frequency of administration. Common side effects of crizotinib may include nausea, vomiting, diarrhea, and elevated liver enzymes. However, these side effects are generally manageable and may lessen over time as the body adjusts to the medication.